SCHEDULE 13D/A: Fosun Pharma Transfers Significant Stake in Nature's Sunshine Products to U.S. Subsidiary

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has transferred 2,854,607 shares of Nature's Sunshine Products, Inc. common stock to its wholly-owned U.S. subsidiary, Fosun Pharma USA Inc., as disclosed in an amended Schedule 13D filing.

Summary

• This Amendment No. 2 to Schedule 13D reports the transfer of 2,854,607 shares of Nature's Sunshine Products, Inc. common stock from Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma") to its wholly-owned subsidiary, Fosun Pharma USA Inc. ("FPUSA").
• FPUSA has been added as an additional Reporting Person in this filing.
• As of April 18, 2025, there are 18,350,801 shares of Common Stock outstanding for Nature's Sunshine Products, Inc.
• Fosun Pharma beneficially owns an aggregate of 2,918,774 shares, representing 15.9% of the class.
• FPUSA directly owns 2,854,607 shares, representing 15.6% of the class.
• Fosun Industrial Co., Limited, another subsidiary of Fosun Pharma, directly owns 64,167 shares.
• Fosun Pharma, as the parent, indirectly beneficially owns all 2,918,774 shares held by FPUSA and Fosun Industrial.

Sentiment

Score: 5

Explanation: The document is neutral, primarily reporting an internal corporate restructuring of share ownership without indicating significant positive or negative implications for the Issuer's operations or financial performance.

Positives

• The transfer of shares to a U.S. subsidiary (FPUSA) could streamline the management of the investment within the U.S. market for Fosun Pharma.
• The continued holding of a significant stake (15.9%) by Fosun Pharma and its subsidiaries indicates ongoing strategic interest in Nature's Sunshine Products, Inc.

Risks

• The Reporting Persons may dispose of all or a portion of their shares, which could impact the market for Nature's Sunshine Products' securities. This decision is subject to various factors including the Issuer's business, prospects, financial condition, market conditions, and general economic conditions.

Future Outlook

The Reporting Persons state that they may dispose of or continue to hold their shares, with decisions based on the Issuer's business, prospects, financial condition, market conditions, other opportunities, and general economic factors. This indicates a flexible investment strategy.

Management Comments

• "The Reporting Persons may dispose or continue to hold all or a portion of the shares of Common Stock reported herein, subject to the Reporting Persons' evaluation of the Issuer's business, prospects and financial condition, the market for such securities, other opportunities available to the Reporting Persons, general economic conditions, stock market conditions and other factors."

Industry Context

Fosun Pharma is an innovation-driven global healthcare company with operations in pharmaceuticals, medical devices & diagnostics, and healthcare services. Its strategic alliance with Sinopharm Group Co., Ltd. extends its capabilities in pharmaceutical commerce. This share transfer is an internal restructuring within a large, diversified global healthcare and investment group, reflecting its ongoing management of its investment portfolio, including its stake in Nature's Sunshine Products, Inc., which operates in the health and wellness sector.

Comparison to Industry Standards

• This document primarily details an internal share transfer and beneficial ownership update, not the financial performance of Nature's Sunshine Products Inc. Therefore, a direct comparison to industry standards for company performance is not applicable based solely on this filing. The filing does not provide specific comparable companies, projects, or results for Nature's Sunshine Products Inc.

Legal Proceedings

• The Reporting Persons (Fosun Pharma and FPUSA) have not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) in the past five years.
• The Reporting Persons have not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction which resulted in a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violations with respect to such laws in the last five years.

Related Party Transactions

• The transfer of 2,854,607 shares of Common Stock from Fosun Pharma to its wholly-owned subsidiary, FPUSA, on June 5, 2025, constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The transfer of shares to a U.S. subsidiary might indicate a more focused management of the investment by the Fosun group, but the overall beneficial ownership percentage by the group remains substantial, suggesting continued strategic interest. The possibility of future dispositions is noted, which could impact market liquidity and share price if large blocks are sold.
• Employees, Customers, Suppliers, Creditors: The document does not contain information directly impacting these stakeholders of Nature's Sunshine Products Inc. as it pertains to an ownership restructuring of a significant shareholder, not the operational aspects of the Issuer.

Next Steps

• The Reporting Persons will continue to evaluate their investment in Nature's Sunshine Products, Inc. based on various factors, which may lead to future dispositions or continued holding of shares.

Key Dates

Keywords

Nature's Sunshine Products, Fosun Pharma, Fosun Pharma USA Inc., Schedule 13D, beneficial ownership, share transfer, pharmaceuticals, healthcare, investment holding, SEC filing